Mass screening of prostate cancer in Vietnam: Current status and our opinions

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 6, 2010, Pages 673-676

  Vu Le, Chuyen ^a   Dao, Oanh Quang ^a   Khac Tran, Linh Ngoc ^a  

^a Binh Dan Hospital   (Viet Nam)

Author keywords

Outcome; Prostate cancer; Prostate cancer screening

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN BLOOD LEVEL; ANTIANDROGEN THERAPY; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; EARLY DIAGNOSIS; HEALTH PROGRAM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; VIET NAM;

EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; PREVALENCE; PROSTATIC NEOPLASMS; VIETNAM;

EID: 78149385357     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.12.008     Document Type: Review

References (11)

1. Andriole G.L., Levin D.L., Crawford E.D., et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005 Mar 16, 97:433-438.
2. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
3. Schmid H.P., Prikler L., Semjonow A. Problems with prostate-specific antigen screening: A critical review. Recent results. Cancer Res 2003, 163:226-231. Discussion 64-6.
4. Schroder F.H. Detection of prostate cancer: The impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Can J Urol 2005, 12(Suppl 1):2-6. Discussion 92-3.
5. Carter H.B., Allaf M.E., Partin A.W. Diagnosis and staging of prostate cancer. Campbell-Walsh Urology 2008, Vol. I. Sauders, Philadelphia, Chapt 94.
6. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998, 279:1542-1547.
7. Carroll P., Coley C., McLeod D., et al. Prostate-specific antigen best practice policy, part I: Early detection and diagnosis of prostate cancer. Urology 2001, 57:217-224.
8. Jhaveri F.M., Klein E.A., Kupelian P.A., et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 1999, 17:3167-3172.
9. Derweesh I.H., Kupelian P.A., Zippe C., et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 2004, 22:300-306.
10. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
11. Gia Tran Xuan GNI per capital-the number and reality 2008, (available from: http://www.gso.gov.vn/).